Cargando…
A Monte Carlo Determination of Dose and Range Uncertainties for Preclinical Studies with a Proton Beam
SIMPLE SUMMARY: If reference studies can be found on the uncertainties linked to the clinical context of proton therapy, they, although equally critical, are very patchy in a preclinical context, and are specific to each beam line. This work provides the community with a complete assessment of the s...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071150/ https://www.ncbi.nlm.nih.gov/pubmed/33920758 http://dx.doi.org/10.3390/cancers13081889 |
_version_ | 1783683633376133120 |
---|---|
author | Bongrand, Arthur Koumeir, Charbel Villoing, Daphnée Guertin, Arnaud Haddad, Ferid Métivier, Vincent Poirier, Freddy Potiron, Vincent Servagent, Noël Supiot, Stéphane Delpon, Grégory Chiavassa, Sophie |
author_facet | Bongrand, Arthur Koumeir, Charbel Villoing, Daphnée Guertin, Arnaud Haddad, Ferid Métivier, Vincent Poirier, Freddy Potiron, Vincent Servagent, Noël Supiot, Stéphane Delpon, Grégory Chiavassa, Sophie |
author_sort | Bongrand, Arthur |
collection | PubMed |
description | SIMPLE SUMMARY: If reference studies can be found on the uncertainties linked to the clinical context of proton therapy, they, although equally critical, are very patchy in a preclinical context, and are specific to each beam line. This work provides the community with a complete assessment of the sources of uncertainties for a preclinical proton beam line. This aims to ensure that, in this line, the biological results observed and the dose–response relationships are obtained without any bias. Despite being specific to a preclinical line, the results presented here can be transposed to other types of proton preclinical facilities, and thus allow us to effectively compare them to one another. ABSTRACT: Proton therapy (PRT) is an irradiation technique that aims at limiting normal tissue damage while maintaining the tumor response. To study its specificities, the ARRONAX cyclotron is currently developing a preclinical structure compatible with biological experiments. A prerequisite is to identify and control uncertainties on the ARRONAX beamline, which can lead to significant biases in the observed biological results and dose–response relationships, as for any facility. This paper summarizes and quantifies the impact of uncertainty on proton range, absorbed dose, and dose homogeneity in a preclinical context of cell or small animal irradiation on the Bragg curve, using Monte Carlo simulations. All possible sources of uncertainty were investigated and discussed independently. Those with a significant impact were identified, and protocols were established to reduce their consequences. Overall, the uncertainties evaluated were similar to those from clinical practice and are considered compatible with the performance of radiobiological experiments, as well as the study of dose–response relationships on this proton beam. Another conclusion of this study is that Monte Carlo simulations can be used to help build preclinical lines in other setups. |
format | Online Article Text |
id | pubmed-8071150 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80711502021-04-26 A Monte Carlo Determination of Dose and Range Uncertainties for Preclinical Studies with a Proton Beam Bongrand, Arthur Koumeir, Charbel Villoing, Daphnée Guertin, Arnaud Haddad, Ferid Métivier, Vincent Poirier, Freddy Potiron, Vincent Servagent, Noël Supiot, Stéphane Delpon, Grégory Chiavassa, Sophie Cancers (Basel) Article SIMPLE SUMMARY: If reference studies can be found on the uncertainties linked to the clinical context of proton therapy, they, although equally critical, are very patchy in a preclinical context, and are specific to each beam line. This work provides the community with a complete assessment of the sources of uncertainties for a preclinical proton beam line. This aims to ensure that, in this line, the biological results observed and the dose–response relationships are obtained without any bias. Despite being specific to a preclinical line, the results presented here can be transposed to other types of proton preclinical facilities, and thus allow us to effectively compare them to one another. ABSTRACT: Proton therapy (PRT) is an irradiation technique that aims at limiting normal tissue damage while maintaining the tumor response. To study its specificities, the ARRONAX cyclotron is currently developing a preclinical structure compatible with biological experiments. A prerequisite is to identify and control uncertainties on the ARRONAX beamline, which can lead to significant biases in the observed biological results and dose–response relationships, as for any facility. This paper summarizes and quantifies the impact of uncertainty on proton range, absorbed dose, and dose homogeneity in a preclinical context of cell or small animal irradiation on the Bragg curve, using Monte Carlo simulations. All possible sources of uncertainty were investigated and discussed independently. Those with a significant impact were identified, and protocols were established to reduce their consequences. Overall, the uncertainties evaluated were similar to those from clinical practice and are considered compatible with the performance of radiobiological experiments, as well as the study of dose–response relationships on this proton beam. Another conclusion of this study is that Monte Carlo simulations can be used to help build preclinical lines in other setups. MDPI 2021-04-15 /pmc/articles/PMC8071150/ /pubmed/33920758 http://dx.doi.org/10.3390/cancers13081889 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bongrand, Arthur Koumeir, Charbel Villoing, Daphnée Guertin, Arnaud Haddad, Ferid Métivier, Vincent Poirier, Freddy Potiron, Vincent Servagent, Noël Supiot, Stéphane Delpon, Grégory Chiavassa, Sophie A Monte Carlo Determination of Dose and Range Uncertainties for Preclinical Studies with a Proton Beam |
title | A Monte Carlo Determination of Dose and Range Uncertainties for Preclinical Studies with a Proton Beam |
title_full | A Monte Carlo Determination of Dose and Range Uncertainties for Preclinical Studies with a Proton Beam |
title_fullStr | A Monte Carlo Determination of Dose and Range Uncertainties for Preclinical Studies with a Proton Beam |
title_full_unstemmed | A Monte Carlo Determination of Dose and Range Uncertainties for Preclinical Studies with a Proton Beam |
title_short | A Monte Carlo Determination of Dose and Range Uncertainties for Preclinical Studies with a Proton Beam |
title_sort | monte carlo determination of dose and range uncertainties for preclinical studies with a proton beam |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071150/ https://www.ncbi.nlm.nih.gov/pubmed/33920758 http://dx.doi.org/10.3390/cancers13081889 |
work_keys_str_mv | AT bongrandarthur amontecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam AT koumeircharbel amontecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam AT villoingdaphnee amontecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam AT guertinarnaud amontecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam AT haddadferid amontecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam AT metiviervincent amontecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam AT poirierfreddy amontecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam AT potironvincent amontecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam AT servagentnoel amontecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam AT supiotstephane amontecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam AT delpongregory amontecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam AT chiavassasophie amontecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam AT bongrandarthur montecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam AT koumeircharbel montecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam AT villoingdaphnee montecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam AT guertinarnaud montecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam AT haddadferid montecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam AT metiviervincent montecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam AT poirierfreddy montecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam AT potironvincent montecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam AT servagentnoel montecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam AT supiotstephane montecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam AT delpongregory montecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam AT chiavassasophie montecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam |